Results 71 to 80 of about 8,272 (178)

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad, Eugene Brailovski, Jacqueline Dela‐Pena, Melinda Cook, Michael Rosenzweig, Heather Jolie Landau   +5 more
wiley   +1 more source

Pulmonary light chain deposition disease: Case series and review of the literature

Radiology Case Reports
Pulmonary light chain deposition disease is a rare entity characterized by immunoglobulin deposition within the lung parenchyma with pathologic features distinct from pulmonary amyloidosis.
Tomas V. Gonzalez, MD, Anja C. Roden, MD, Brian J. Bartholmai, MD, Rebecca M. Lindell, MD   +3 more
doaj   +1 more source

Real‐World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild‐Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate and timely diagnosis. This retrospective cohort study assessed real‐world diagnostic workups
Muhamed Baljevic, Haechung Chung, Jose Alvir, Patrick Feron, Aaron Crowley, Darrin Benjumea, Yong Chen, Cindi Pankratova   +7 more
wiley   +1 more source

Hepatic Monoclonal Light‐ and Heavy‐Chain Deposition Disease Presenting as Noncirrhotic Portal Hypertension With Ascites

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Monoclonal immunoglobulin deposition disease (MIDD) is a plasma cell disorder where immunoglobulin light‐ and/or heavy‐chains accumulate in various organs. Hepatic involvement can be challenging to diagnose, as manifestations are protean and Congo red staining is negative.
Bella L. Liu, Helmut G. Rennke, Lei Zhao, Kayla R. Elliott, Yuxin Liu, Stephen D. Zucker   +5 more
wiley   +1 more source

A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only

Organ Medicine, Volume 3, Issue 2, Page 119-124, June 2026.
This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai, Yuanyue Guan, Shiwei Cui, Yuan Gao, Zhipeng Zhao, Rui Li, Li Song, Xiuying Zhao, Runqing Li   +8 more
wiley   +1 more source

Púrpura: manifestação de amiloidose sistémica primária.

Acta Médica Portuguesa, 2009
Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs. The mucocutaneous manifestations occur in about 30-40% of the cases and are
Sara Lestre, Andreia Gonçalves, Alexandre João, Ana Ferreira, Margarida Apetato   +4 more
doaj   +1 more source

Daratumumab for Immunoglobulin Light Chain Amyloidosis [PDF]

Oncology & Haematology, 2021
Theodorakakou, Foteini, Dimopoulos, Meletios A., Kastritis, Efstathios   +2 more
openaire   +2 more sources

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma

HemaSphere, Volume 10, Issue 6, June 2026.
Gala Vega, Daniel Morillo, Christine Riedhammer, Febe Smits, Aishee Bag, Kelly Julian, Natalia Tovar Gomis, Carmen Montes Gaisan, Maria Aranzazu Bermudez, Mansi R. Shah, Ghulam Rehman Mohyuddin, Binod Dhakal, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Niels W. C. J. van de Donk, Rajshekhar Chakraborty, Meera Mohan   +18 more
wiley   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, Volume 208, Issue 6, Page 2059-2068, June 2026.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, Volume 208, Issue 6, Page 2096-2103, June 2026.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source